Related Experiment Video
Updated: Jul 3, 2026
07:28
Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
Tigecycline pharmacokinetic/pharmacodynamic update
1Department of Medical Microbiology, Bristol Centre for Antimicrobial Research and Evaluation, University of Bristol and North Bristol NHS Trust, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK. alasdair.macgowan@nbt.nhs.uk
The Journal of Antimicrobial Chemotherapy
|August 14, 2008
Summary
Recent data reveal important pharmacokinetic and pharmacodynamic information for tigecycline in humans. These findings help clarify the clinical utility of tigecycline for specific infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Pharmacy
Background:
- Tigecycline is a broad-spectrum antibiotic used for serious infections.
- Understanding its pharmacokinetics and pharmacodynamics is crucial for optimizing treatment.
- Recent studies have provided new insights into tigecycline's behavior in the human body.
Purpose of the Study:
- To review and summarize recent data on the pharmacokinetics and pharmacodynamics of tigecycline in humans.
- To establish drug exposure-response relationships for key indications.
- To define the clinical role of tigecycline based on current evidence.
Main Methods:
- Review of recently published pharmacokinetic and pharmacodynamic studies.
- Analysis of data from infected patients, including tissue distribution.
- Establishment of drug exposure-response relationships for specific infection types.
Main Results:
- Significant pharmacokinetic data are available from studies in infected patients.
- Information on tigecycline's tissue distribution is now established.
- Drug exposure-response relationships have been defined for complicated skin and skin structure infections and intra-abdominal infections.
Conclusions:
- Pharmacodynamic studies in humans present challenges due to mixed infections and surgical impact.
- The reviewed data provide a clearer understanding of tigecycline's clinical role.
- This summary aids clinicians in optimizing tigecycline therapy.
Related Concept Videos
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:10Pharmacokinetics: Overview
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
01:20Chronopharmacokinetics: Time-Dependent Pharmacokinetics
Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...